Louisville, KY, United States of America

Joseph A Burlison

This inventor holds 14 USPTO granted patents and 3 published patent applications and 5 EPO patents. Top assignees: Synta Pharmaceuticals Corporation, University Of Louisville Research Foundation, Inc.. Active years: 2012-2026.

USPTO Granted Patents = 14 (Patent Applications = 3)

% Patents Active = 57.1

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 4.8

ph-index = 6

Forward Citations = 131(Granted Patents)

Location History:

Burlington, MA (US) (2012 - 2014)
North Reading, MA (US) (2013 - 2014)
Louisville, KY (US) (2015 - 2023)

Company Filing History:

9 out of 162

Synta Pharmaceuticals Corporation

patents

5 out of 398

University Of Louisville Research Foundation, Inc.

patents

Years Active: 2012-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12582660 - INHIBITORS OF THE RAS ONCOPROTEIN, METHODS OF MAKING AND METHODS OF USE THEREOF (2026-03-24),

2. 11708330 - Compounds, compositions, methods for treating diseases, and methods for preparing compounds (2023-07-25),

3. 11679098 - Methods for treating diseases (2023-06-20),

4. 11312690 - Compounds, compositions, methods for treating diseases, and methods for preparing compounds (2022-04-26),

5. 10774046 - Inhibitors for the treatment of cancer and related methods (2020-09-15),

6. 9539243 - Triazole compounds that modulate HSP90 activity (2017-01-10),

7. 9156836 - Tricyclic triazole compounds that modulate HSP90 activity (2015-10-13),

8. 9126953 - Triazole compounds that modulate HSP90 activity (2015-09-08),

9. 8937094 - Triazole compounds that modulate HSP90 activity (2015-01-20),

10. 8748424 - Triazole compounds that modulate Hsp90 activity (2014-06-10),

11. 8648071 - Hydrazonamide compounds that modulate Hsp90 activity (2014-02-11),

12. 8486932 - Triazole compounds that modulate Hsp90 activity (2013-07-16),

13. 8299107 - Triazole compounds that modulate HSP90 activity (2012-10-30),

14. 8106083 - Triazole compounds that modulate HSP90 activity (2012-01-31),

Title: The Innovative Journey of Joseph A. Burlison in Pharmaceutical Inventions

Introduction

Joseph A. Burlison, an accomplished inventor based in Louisville, Kentucky, has made significant contributions to the field of pharmaceutical research and development. With a remarkable portfolio of 13 patents, his work focuses on discovering and formulating innovative compounds and methodologies aimed at treating various diseases, including challenging conditions such as cancer.

Latest Patents

Burlison's latest patents revolve around compounds, compositions, and methods for treating diseases. Some embodiments of his invention include creative compounds represented by specific formulas. His work has led to the development of pharmaceutical compositions that utilize these inventive compounds for treating diseases. Notably, his methods include using these compounds effectively in pharmaceutical settings to combat diseases, including chemo-resistant cancer. The additional embodiments of his inventions provide a broader understanding of how these compounds can be manufactured and applied in therapeutic contexts.

Career Highlights

Throughout his career, Joseph A. Burlison has collaborated with renowned organizations, notable among them being Synta Pharmaceuticals Corporation and the University of Louisville Research Foundation, Inc. These affiliations have empowered him to advance his research and apply his innovative ideas in practical settings.

Collaborations

Burlison has worked alongside esteemed colleagues, including Weiwen Ying and Dinesh U. Chimmanamada. These collaborations have enriched his research endeavors, leading to the development of groundbreaking inventions that contribute to the medical field.

Conclusion

Joseph A. Burlison stands as a prominent figure in pharmaceutical innovation, continually striving to enhance treatment options for various diseases through his inventive compounds and methodologies. His extensive patent portfolio is a testament to his commitment to advancing medical science and improving patient outcomes.